摘要
目的观察以替吉奥联合顺铂(SP)方案化疗,并行同步调强放疗治疗晚期限局性非小细胞肺癌的疗效及安全性。方法初治晚期限局性非小细胞肺癌42例,行替吉奥40～60 mg/m2,2次/d,口服d1～14联合顺铂25 mg/m2,1次/d,静脉滴注d1～3化疗,每3周为1周期,并于第1周期开始同步行调强放疗DT 58～66 Gy/29～33 F。其后再行2周期SP方案巩固化疗。结果 42例中有39例完成观察,总有效率(RR)为69.2%,疾病控制率(DCR)为87.2%。中位无进展生存期(PFS)为11.2个月,1年生存率为84.6%。鳞癌和非鳞癌患者疗效相当。常见的3～4级毒性反应为白细胞下降、粒细胞下降、贫血等。结论替吉奥联合顺铂同步调强放疗治疗晚期限局性非小细胞肺癌安全有效,且对于各种组织学类型均有效,为晚期限局性非小细胞肺癌的治疗提供了一种新的选择。
Objective To evaluate the efficacy and toxicity of TCO and cisplatin with intensity modulated radiation therapy （IMRT） for locally advanced non-small-cell lung cancer（NSCLC）. Methods The 42 patients with stage m NSCLC were initially treated with TCO （orally in 40-60 mg/m2 bid, on days 1-14） and cisplatin （25 mg/ m2 ivdrip on day 1-3） repeated every 3 weeks; concurrently with IMRT （58-66 Gy/29-33 F） beginning at the first cycle chemotherapy. Two further cycles of the same SP regimen were administered as a consolidation chemotherapy. Results Of 42 patients, 39 were evaluated. The total response rate was 69.2%, and the disease control rate was 87.2%. The median survival free progression was 11.2 months, and the 1-year survival rate was 84.6%. The efficacy were similar in both squamous and non-squamous cancer histology. The most common toxic reaction of grade 3-4 were leucopenia, neutropenia and anemia. Conclusion The combination chemotherapy plus cisplatin with concurrent intensity modulated radiation therapy showed a promising efficacy and acceptable toxicity against locally advanced NCSLC regardless of histology, and is thus a new treatment option.
出处
《实用医药杂志》
2012年第12期1057-1059,共3页
Practical Journal of Medicine & Pharmacy
关键词
非小细胞肺癌
同步调强放疗
替吉奥(替加氟+吉美嘧啶+奥替拉西钾)
顺铂
Non-small-cell lung cancer
, Concurrent intensity modulated radiotherapy（IMRT）
TCO（tegafur- CDHP-potassium oxonate）
Cisplatin
